Matt Davidson Sells 3,516 Shares of Verrica Pharmaceuticals Inc (VRCA) Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 3,516 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $10.54, for a total value of $37,058.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Tuesday, April 16th, Matt Davidson sold 3,193 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.39, for a total value of $33,175.27.
  • On Thursday, April 11th, Matt Davidson sold 18,850 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.16, for a total value of $191,516.00.
  • On Monday, April 8th, Matt Davidson sold 12,385 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.67, for a total value of $132,147.95.
  • On Wednesday, April 3rd, Matt Davidson sold 13,436 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.37, for a total value of $139,331.32.
  • On Tuesday, March 26th, Matt Davidson sold 13,667 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.50, for a total value of $157,170.50.
  • On Thursday, March 21st, Matt Davidson sold 7,920 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.27, for a total value of $97,178.40.
  • On Monday, March 18th, Matt Davidson sold 11,626 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.26, for a total value of $142,534.76.
  • On Wednesday, March 13th, Matt Davidson sold 25,045 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.55, for a total value of $289,269.75.
  • On Friday, March 8th, Matt Davidson sold 20,558 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.72, for a total value of $240,939.76.
  • On Tuesday, March 5th, Matt Davidson sold 25,830 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $12.46, for a total value of $321,841.80.

VRCA stock opened at $10.64 on Friday. Verrica Pharmaceuticals Inc has a twelve month low of $6.44 and a twelve month high of $23.29. The firm has a market capitalization of $273.52 million and a price-to-earnings ratio of -7.55.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Thursday, March 7th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). As a group, sell-side analysts expect that Verrica Pharmaceuticals Inc will post -1.14 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in VRCA. Vanguard Group Inc increased its stake in Verrica Pharmaceuticals by 950.7% in the third quarter. Vanguard Group Inc now owns 292,489 shares of the company’s stock worth $4,753,000 after purchasing an additional 264,651 shares during the period. Vanguard Group Inc. increased its stake in Verrica Pharmaceuticals by 950.7% in the third quarter. Vanguard Group Inc. now owns 292,489 shares of the company’s stock worth $4,753,000 after purchasing an additional 264,651 shares during the period. BlackRock Inc. purchased a new stake in Verrica Pharmaceuticals in the third quarter worth $4,145,000. Diag Capital Management LP purchased a new stake in Verrica Pharmaceuticals in the fourth quarter worth $937,000. Finally, Kornitzer Capital Management Inc. KS increased its stake in Verrica Pharmaceuticals by 52.2% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 327,420 shares of the company’s stock worth $2,668,000 after purchasing an additional 112,275 shares during the period. Institutional investors and hedge funds own 32.86% of the company’s stock.

VRCA has been the subject of a number of analyst reports. HC Wainwright initiated coverage on Verrica Pharmaceuticals in a research report on Thursday, February 21st. They issued a “buy” rating and a $20.00 price target for the company. Zacks Investment Research downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 5th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.25.

ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2019/04/21/matt-davidson-sells-3516-shares-of-verrica-pharmaceuticals-inc-vrca-stock.html.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Recommended Story: Analyzing a company’s cash flow statement

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.